Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis.

In TRACER patients with NSTE (nonST-segment elevation)-ACS and peripheral artery disease (PAD), there was a tendency of reduced ischemic end points and peripheral revascularization which, however, did not reach statistical significance. 16 Platelet activation, particularly induced by thrombin, plays a key role in atherothrombotic events in patients with stable atherosclerosis. 17 After it had been shown that vorapaxar reduces death due to cardiovascular causes in patients with unstable angina pectoris and nonST-elevation myocardi

also in 111,027 other papers